AZN offically announces taking Selumetinib into Phase III this year
AstraZeneca Plc (AZN) will move three experimental cancer treatments into late-stage development as generic competition for its best-selling drugs intensifies.
The U.K.’s second-biggest drugmaker is advancing development of moxetumomab pasudotox for hairy cell leukemia, olaparib for platinum-sensitive relapsed ovarian cancer and selumetinib for non-small cell lung cancer patients with the KRAS genetic mutation, the London-based company said today in a statement.
Selumetinib, which the company licensed from Array Biopharma (ARRY), will begin testing in a late-stage trial in non-small cell lung cancer patients with a KRAS gene mutation during the second half of the year. AstraZeneca is also testing the treatment in melanoma patients with the same genetic mutation and for advanced pancreatic cancer